These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33616313)

  • 21. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Medical treatment of renal cell carcinoma].
    Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
    Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy.
    Sun M; Bianchi M; Hansen J; Trinh QD; Karakiewicz PI
    J Clin Oncol; 2012 Nov; 30(31):3901; author reply 3902. PubMed ID: 22987077
    [No Abstract]   [Full Text] [Related]  

  • 24. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
    De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
    Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
    Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe.
    Meza L; Bergerot PG; Agarwal N; Pal SK
    Ann Oncol; 2021 Jan; 32(1):12-14. PubMed ID: 33121996
    [No Abstract]   [Full Text] [Related]  

  • 27. Tivozanib in renal cell carcinoma.
    Figlin R
    Clin Adv Hematol Oncol; 2013 Jan; 11(1):43-5. PubMed ID: 23416862
    [No Abstract]   [Full Text] [Related]  

  • 28. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
    Glen H
    Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Present state of target therapy for disseminated renal cell carcinoma.
    Waalkes S; Kramer M; Herrmann TR; Schrader AJ; Kuczyk MA; Merseburger AS
    Immunotherapy; 2010 May; 2(3):393-8. PubMed ID: 20635903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.
    Tremblay G; McElroy HJ; Westley T; Meier G; Misurski D; Guo M
    PLoS One; 2019; 14(3):e0212899. PubMed ID: 30835737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic therapy for metastatic renal cell carcinoma.
    Kroog GS; Motzer RJ
    Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced kidney cancer: treating the elderly.
    Zustovich F; Novara G
    Expert Rev Anticancer Ther; 2013 Dec; 13(12):1389-98. PubMed ID: 24224483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in treatment of metastatic renal cell carcinoma.
    Gong J; Gerendash B; Dizman N; Khan A; Pal SK
    Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Fléchon A; Boyle H; Négrier S
    Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on targeted therapy in metastatic renal cell carcinoma.
    Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
    Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
    Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
    Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy in renal cell carcinoma.
    Vakkalanka BK; Rini BI
    Curr Opin Urol; 2008 Sep; 18(5):481-7. PubMed ID: 18670271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.